



MEDIA RELEASE

25 October 2007

FOR IMMEDIATE RELEASE

NeuroDiscovery Ltd has tied up with TetraQ

NeuroDiscovery Ltd, neurology focused research and development company has tied up with TetraQ of Australia to market the safety pharmacology services of NeuroDiscovery's 100% subsidiary, NeuroSolutions Ltd in Australasia.

University of Queensland based TetraQ is the premier contract research organization in Australia providing integrated preclinical services to the global pharmaceutical and biotechnology industries. For this reason TetraQ has been chosen to market NeuroSolutions' safety pharmacology services in Australasia. This includes the Qpatch, an automated electrophysiology device to screen drugs for potential adverse cardiac effects (commonly known as a hERG screening).

hERG screening is a crucial step in the process of discovering new medicines. The centerpiece of NeuroSolutions' leading edge electrophysiology and safety pharmacology services to the global drug discovery industry is a UK based hERG testing laboratory. Pharmaceutical and biotech companies are required to undertake a rigorous series of tests to evaluate any potential risks associated with their drugs. hERG testing was incorporated into international guidelines for new pharmaceuticals for human use after a number of important drugs were withdrawn from the US market following reports of heart malfunctions in patients who had been prescribed them.

"We are looking forward to working with TetraQ on marketing our hERG screening services in Australasia to expand the global reach of our profitable service business" said NeuroDiscovery's Chairman, Dr Mark Treherne.

TetraQ's Business Development Manager, Rose-marie Pennisi said becoming involved with NeuroSolutions' hERG testing program would complement the Queensland company's range of customised preclinical services and reputation for research excellence.

"The superior quality of the data generated by the QPatch -and the interpretation of the test results differentiates NeuroSolutions from other hERG testing providers. Both companies share a commitment to high standards and an understanding of the global market." Ms Pennisi said.

- ENDS -

Media Enquiries:

For more information please contact

Rose-Marie Pennisi, TetraQ on P +617 3365 4037 | M +61 437 112 549 | E r.pennisi@tetraq.com.au

Leanne Wyvill, UniQuest on P +617 3365 4037 | M +617 409 767 199

Queensland Clinical Trials Network Inc.

PO Box 2366, Toowong DC Q 4066

AUSTRALIA

www.qctn.com.au